GLMD Stock: Galmed Pharmaceuticals Ltd. Stock Price, Analysis & Insights
Get live glmd stock price $1.18, comprehensive Galmed Pharmaceuticals Ltd. stock analysis, charts, news, and expert forecast. Real-time glmd stock data and investment insights.
Loading chart...
Company Overview
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Company Information
- CEO
- Allen Baharaff
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
Contact Information
- Website
- https://www.galmedpharma.com
- Address
- 16 Tiomkin Street
- Country
- IL
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.28) may provide portfolio stability
Business Model & Strategy
Galmed Pharmaceuticals Ltd. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Allen Baharaff, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Galmed Pharmaceuticals Ltd. competes in the Biotechnology within the broader Healthcare. With 2.7 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Galmed Pharmaceuticals Ltd. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Galmed Pharmaceuticals Ltd. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Galmed Pharmaceuticals Ltd. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Galmed Pharmaceuticals Ltd.
- ⚠Investors should consider how Galmed Pharmaceuticals Ltd. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
2.68M
P/E Ratio
-0.21
Beta
0.28
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 2.68M market capitalization
- Trading Volume: 17.48M shares traded today
- Price Range: 52-week range of $1.01 - $3.61
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. (GLMD) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 2.68M, the company represents a significant player in its market. The stock is currently trading at $1.18 with a positivedaily change of 12.84%.
The company's 3 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.21, beta of 0.28, and 52-week price range from $1.01 to $3.61when evaluating investment opportunities.
Why Invest in Galmed Pharmaceuticals Ltd.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Allen Baharaff
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.